Vanda Pharmaceuticals Inc (VNDA)
5.48
-0.10
(-1.79%)
USD |
NASDAQ |
May 17, 16:00
5.485
0.00 (0.00%)
After-Hours: 20:00
Vanda Pharmaceuticals Enterprise Value: -75.22M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | -75.22M |
| May 16, 2024 | -69.40M |
| May 15, 2024 | -82.20M |
| May 14, 2024 | -95.58M |
| May 13, 2024 | -100.24M |
| May 10, 2024 | -100.82M |
| May 09, 2024 | -102.57M |
| May 08, 2024 | -82.20M |
| May 07, 2024 | -75.22M |
| May 06, 2024 | -112.46M |
| May 03, 2024 | -110.13M |
| May 02, 2024 | -121.77M |
| May 01, 2024 | -116.54M |
| April 30, 2024 | -117.12M |
| April 29, 2024 | -113.63M |
| April 26, 2024 | -125.27M |
| April 25, 2024 | -133.42M |
| April 24, 2024 | -128.76M |
| April 23, 2024 | -124.69M |
| April 22, 2024 | -114.79M |
| April 19, 2024 | -96.76M |
| April 18, 2024 | -104.91M |
| April 17, 2024 | -89.19M |
| April 16, 2024 | -158.45M |
| April 15, 2024 | -157.86M |
| Date | Value |
|---|---|
| April 12, 2024 | -154.37M |
| April 11, 2024 | -145.06M |
| April 10, 2024 | -145.06M |
| April 09, 2024 | -140.41M |
| April 08, 2024 | -131.68M |
| April 05, 2024 | -113.63M |
| April 04, 2024 | -107.82M |
| April 03, 2024 | -100.25M |
| April 02, 2024 | -166.59M |
| April 01, 2024 | -154.37M |
| March 31, 2024 | -154.95M |
| March 28, 2024 | -151.78M |
| March 27, 2024 | -164.44M |
| March 26, 2024 | -166.17M |
| March 25, 2024 | -165.59M |
| March 22, 2024 | -164.44M |
| March 21, 2024 | -163.29M |
| March 20, 2024 | -169.62M |
| March 19, 2024 | -171.92M |
| March 18, 2024 | -172.50M |
| March 15, 2024 | -169.05M |
| March 14, 2024 | -169.62M |
| March 13, 2024 | -167.32M |
| March 12, 2024 | -165.02M |
| March 11, 2024 | -157.83M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-295.40M
Minimum
Nov 09 2023
800.06M
Maximum
Jun 30 2021
230.76M
Average
246.57M
Median
Enterprise Value Benchmarks
| ADMA Biologics Inc | 2.220B |
| INVO Bioscience Inc | 11.23M |
| Nektar Therapeutics | 33.02M |
| Ligand Pharmaceuticals Inc | 1.235B |
| Invivyd Inc | 96.97M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.146M |
| Revenue (Quarterly) | 47.46M |
| Total Expenses (Quarterly) | 56.70M |
| EPS Diluted (Quarterly) | -0.07 |
| Gross Profit Margin (Quarterly) | 92.75% |
| Profit Margin (Quarterly) | -8.74% |
| Earnings Yield | -1.42% |
| Normalized Earnings Yield | -1.416 |